300314.SZ · 戴维医疗
China A-shares · RS rating 89 · As of 2026-10-14
| Price | 11.95 CNY |
|---|---|
| 1-day change | -2.0% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 86 / 94 / 51 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 38 / 49 / 28 |
| Industry group (rank) | Medical-Products (64) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +23.3% |
| Distance from 52-week high | +22.1% |
| Market cap (USD) | $553.9M |